Healthcare >> CEO Interviews >> October 12, 2001
DR. TED W. LOVE was appointed President and Chief Executive Officer of
Nuvelo, Inc., in March 2001, having been appointed President and Chief
Operating Officer of the company in January 2001. He has served as a
Director of the company since February 2001. Dr. Love joined Nuvelo from
Advanced Medicine Inc., where he served as Senior Vice President of
Development from February 1998 to January 2001. Previously, Dr. Love
spent six years at Genentech Inc., holding a number of senior management
positions in medical affairs and product development. As Vice President
of Product Development and Regulatory Affairs at Genentech, Dr. Love
oversaw all drugs in development including Herceptin, Rituxan and
TNKase. He also served as Chairman of Genentech's Product Development
Committee. Dr. Love earned a BA in Molecular Biology from Haverford
College and an MD at Yale Medical School. He completed residency and
fellowship training in internal medicine and cardiology at Massachusetts
General Hospital and Harvard Medical School. Following residency
training, Dr. Love joined the faculty of Massachusetts General in the
Department of Cardiology. He also serves as a Trustee on the Board of
Managers of Haverford College and as a member of the Board of Directors
of Predix Pharmaceuticals, Inc. Profile
over the past year or so that investors should focus on?
Dr. Love: I think the main thing that we've done is made a very
